1. Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results. (March 2017) Authors: Wuerstlein, R.; Grischke, E.M.; Gluz, O.; Kates, R.; Persoon, M.; Thill, M.; Hasmueller, S.; Knauer, M.; Pusch, R.; Harbeck, N. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. (2nd July 2016) Authors: Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; von Schumann, R.; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E.; Harbeck, N. Journal: Current medical research and opinion Issue: Volume 32:Number 7(2016:Jul.) Page Start: 1217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗